Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers

The goal of this prospective, single-center, open-label, dose-escalation study is to evaluate the safety, tolerability, and preliminary efficacy of CD-001 in patients with advanced head and neck cancers who have experienced disease progression (PD) or intolerance to standard systemic therapy (or lack thereof). The main question\[s\] it aims to answer: * What is the safety and tolerability profile of CD-001 across escalating doses? * What is the preliminary efficacy of CD-001 in this patient population?

NCT Number	NCT07072325
Lead Sponsor	West China Hospital
Conditions	Malignant Neoplasm, Head & Neck Cancer, Head and Neck Cancer, Advanced Head and Neck Carcinoma
Enrollment	9 participants
Start Date	2025-08-10
Primary Completion	2027-08-01 (estimated)
Study Completion	2028-08-31 (estimated)
Updated on ClinicalTrials.gov	2025-08-03